MedTrace Logo

Safety and Efficacy of NYX-783 in Subjects With Post-Traumatic Stress Disorder

NCT04044664 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2022-05-17

Study results available
· View outcomes & findings →

Summary

To evaluate the safety, tolerability, and response profile of NYX-783 in a Post-Traumatic Stress Disorder population.

Conditions

  • Post-Traumatic Stress Disorder

Interventions

DRUG

Placebo oral capsule

Matching placebo capsules.

DRUG

NYX-783

NYX-783 is a small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).

Sponsors & Collaborators

  • Premier Research Group plc

    collaborator UNKNOWN

  • Massachusetts General Hospital

    collaborator OTHER

  • Aptinyx

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-25
Primary Completion
2020-08-05
Completion
2020-08-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04044664 on ClinicalTrials.gov